Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Nortase is an oral enzyme replacement therapy used to treat exocrine pancreatic insufficiency (EPI), a condition where the pancreas does not produce enough digestive enzymes. Unlike traditional pancreatic enzyme products derived from animal sources, Nortase contains acid-stable, plant-based rizoenzymes—specifically lipase (from Rhizopus oryzae), protease, and amylase (both from Aspergillus oryzae). These enzymes begin digesting food in the stomach due to their acid stability, improving nutrient absorption and alleviating symptoms such as bloating, flatulence, diarrhea, and abdominal pain after eating. Nortase is suitable for vegetarians and those who cannot tolerate porcine-derived pancreatin. It is primarily indicated for patients with EPI due to chronic pancreatitis or following partial/total pancreatectomy[1][2][8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on nortase.